7,583.80

+42.40

+0.56%

51,858.40

-125.58

-0.24%

25,421.46

+257.09

+1.02%

2,830.10

+24.22

+0.86%

4.9540

+0.0600

+1.23%

20.41

-0.74

-3.50%

3,938.70

-30.90

-0.78%

77,526.91

+642.16

+0.84%

Crude Oil Dec 26

95.81

-0.65

-0.67%

US Private Equity

10,836.30

-14.33

-0.13%

Dusseldorf - Delayed Quote EUR

BeiGene Ltd (49BA.DU)

314.00 -8.00 (-2.48%)

As of 4:30:16 PM GMT+1. Market Open.

Loading Chart for 49BA.DU

Chart Range Bar

Interval:

In partnership with ChartIQ

Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics

Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics

Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus

Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus

BeOne Medicines to Present at the Jefferies Global Healthcare Conference

BeOne Medicines to Present at the Jefferies Global Healthcare Conference

New Strong Buy Stocks for November 3rd

New Strong Buy Stocks for November 3rd

3 Healthcare Stocks To Watch In October 2026

3 Healthcare Stocks To Watch In October 2026

BeOne Medicines (ONC) Could Be 13% Undervalued As ESMO Data Lifts The Narrative

BeOne Medicines (ONC) Could Be 13% Undervalued As ESMO Data Lifts The Narrative

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.

BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

Mobilize your Website

View Site in Mobile | Classic

Share by: